Frequently Asked Questions

HeAIth is a healthcare AI company building clinical decision support tools where doctors decide, AI assists. Our flagship product, MediScreenAI, uses AI to pre-collect and organise patient information before the doctor consultation. Patients enter their symptoms and information, our AI analyses what's relevant, asks intelligent follow-up questions, then generates a comprehensive ticket for doctors with suggested diagnoses and next actions. Doctors review everything in an easy-to-digest format and make the final clinical decision - transforming 15-minute consultations into 2-minute reviews.

HeAIth was founded by Maximus Smith, a software engineer with a BSc in Mathematics, after successfully using AI to diagnose his own skin condition and save over £200 in private fees. Recognising the NHS's capacity challenges, he built HeAIth as an advanced clinical decision support system designed to integrate into doctor workflows whilst reducing costs.

MediScreenAI works in three steps: (1) Patient Input - Patients are prompted and encouraged to enter as much information as possible about their symptoms and concerns. (2) AI Analysis & Questions - Our intelligent AI system analyses what's relevant, dissects the information, and generates targeted follow-up questions to gather complete clinical context. (3) Doctor Review - The AI creates a comprehensive ticket presenting the patient information in an easy-to-digest format, along with AI-suggested diagnoses and recommended next actions. The doctor reviews everything and makes the final clinical decision. The AI pre-collects and organises - doctors decide and act.

No. MediScreenAI is currently in development and has NOT been approved by the MHRA, FDA, or any regulatory authority. It is not available for clinical use. Information on this website is for healthcare professionals, advisors, and investors only.

We are pursuing MHRA UKCA authorisation as a Class IIb Software as a Medical Device (SaMD). Our regulatory timeline includes MHRA submission in Q2 2026, multi-site clinical validation with NHS trusts, NHS DTAC completion (Cyber Essentials, FHIR), UK Approved Body conformity assessment, Clinical Safety Case Report (DCB0129), and MHRA review process in Q4 2026-Q1 2027. This requires ISO 13485 QMS, Clinical Safety Officer, DCB0129 compliance, DPIA, ICO registration, and full UK GDPR compliance. We are committed to patient safety with no shortcuts.

Patient safety is our top priority through a Clinical Advisory Board of 3-5 practising doctors, rigorous MHRA and ISO compliance, evidence-based design, extensive NHS clinical validation, comprehensive risk management (ISO 14971), and transparent communication about capabilities and limitations. MediScreenAI embodies the principle that doctors decide, AI assists - the AI pre-collection and presentation of information supports clinical judgment without replacing it. Doctors always make the final decision - the AI organises information and suggests options, creating an easy-to-digest review workflow for time-pressured A&E and GP consultations.

We maintain the highest data protection standards through full UK GDPR compliance, NHS DCB0129 and DCB0160 standards, data minimisation, end-to-end encryption, strict role-based access controls, and complete audit logging. For full details, see our Privacy Policy.

Our Clinical Advisory Board will comprise 3-5 practising doctors and frontline clinicians who will guide every aspect of MediScreenAI's development, ensuring genuine clinical insight and real-world healthcare relevance. Board members will shape product decisions, validate clinical accuracy, ensure workflow integration, and maintain focus on patient safety. This will be genuine doctor-led development, not token involvement - your clinical expertise will directly shape how patients are prompted for information, how the AI analyses and organises data, what questions are generated, and how review tickets are presented to doctors for final decision-making. We are currently recruiting founding clinical advisors.

We seek practising clinicians who understand the pressure of initial assessments: active clinical practice (MD, MBBS, NP, PA, or equivalent), frontline experience with diagnostic decision-making, understanding of early assessment challenges, interest in clinical decision support tools, 2-4 hours monthly availability, and commitment to improving diagnostic workflows. Particularly valuable specialties include General Practice/Primary Care, Emergency Medicine/A&E, Acute & Internal Medicine, Urgent Care, NHS Digital Health, and Clinical Governance. Advisory positions include equity compensation and real influence over product development. Apply to join the Clinical Advisory Board

The expected commitment is 2-4 hours monthly, including quarterly advisory meetings (virtual or in-person) and product feedback. The term is 2 years (renewable). All consultation is flexible and scheduled around clinical commitments. As a founding clinical advisor, you receive real influence, equity compensation, early access to the platform, regular engagement, collaborative development with the founding team, founding recognition, and potential involvement in pilot studies.

MediScreenAI focuses on early diagnostic support at the start of the diagnostic journey for undifferentiated presentations common in primary care and emergency settings. The platform encourages comprehensive patient symptom entry, uses AI to intelligently dissect and analyse the information, generates targeted follow-up questions, and creates structured doctor review tickets with AI-suggested diagnoses and next actions. Specific clinical scope will be announced following Clinical Advisory Board finalisation, guided by practising doctors who understand which conditions benefit most from AI-assisted information pre-collection and organisation.

Yes. Seamless integration with existing NHS workflows is a core design priority, including Electronic Health Records (EMIS, SystmOne), NHS Spine, clinical portals, and HL7 FHIR standards. We are working closely with our Clinical Advisory Board to ensure integration is smooth, non-disruptive, and saves clinicians time.

Pricing is being finalised closer to market authorisation with the goal of affordability for all NHS trusts and primary care practices. We are exploring per-clinician subscriptions, per-consultation usage-based pricing, trust-wide licensing, and value-based pricing aligned with patient outcomes to provide clear ROI through improved efficiency. Our AI pre-collection and intelligent organisation system delivers value through time savings - doctors can review comprehensive, AI-organised patient information with suggested diagnoses and next actions in under 2 minutes instead of spending 15 minutes gathering the same information manually.

Our comprehensive roadmap includes: MVP Complete (Q3 2025 - completed), Clinical Advisory Board Formation (Q4 2025 - current phase, recruiting 3-5 founding medical advisors), Initial Product Refinement (Q1 2026 - algorithm refinement, UI/UX optimisation, ISO 13485 QMS, Clinical Safety Officer, DCB0129 compliance, DPIA, ICO registration), Seed Funding Round (Q1-Q2 2026 - £500k-700k target), Clinical Validation & Regulatory Approval (Q2 2026-Q1 2027 - MHRA UKCA submission, multi-site NHS validation, UK Approved Body assessment), UK Market Launch (Q2-Q4 2027 - NHS pilot with 2-3 trusts, general UK availability Q4 2027), and Product Refinement & International Expansion (2028+ - cost optimisation, algorithm improvements, regulatory analysis for EU/US markets).

MediScreenAI MVP is complete (Q3 2025 - diagnostic engine developed, algorithm training completed, platform architecture established, proof of concept validated). We are currently in the Clinical Advisory Board Formation phase (Q4 2025), actively recruiting 3-5 founding medical advisors, establishing advisory board governance, setting strategic direction, and building industry credibility. We are also planning our seed funding round and defining our MHRA pathway. We are not yet in clinical trials and do not have regulatory approval.

We offer non-clinical demonstrations to potential Clinical Advisory Board members, NHS trust decision-makers, investors, and healthcare technology organisations for evaluation purposes only. Demos do not involve real patient data or clinical use. Request a demonstration

We are recruiting 3-5 founding clinical advisors. Practicing GPs or frontline NHS clinicians interested in shaping AI-powered diagnostic support should review the Clinical Advisory Board information, complete the application, participate in a consultation call, and review the advisory agreement. Apply to join

Yes. We are planning a seed funding round in Q1-Q2 2026 with a target of £500k-700k for the regulatory pathway. Allocation: 45% regulatory & compliance (MHRA pathway, ISO certification, Clinical Safety Officer, quality management systems), 35% product development (engineering team, NHS EHR integration, platform refinement, security infrastructure), 15% clinical team & advisory board (clinical advisor compensation, medical director hire, clinical validation team), and 5% operations & legal (company formation, legal compliance, insurance, operational infrastructure). This funding enables us to complete the MHRA UKCA submission, multi-site clinical validation with NHS trusts, and pilot deployment. For investment enquiries: maximus.smith@heaith.co.uk (subject: "Investment Inquiry")

We welcome early engagement from NHS trusts interested in clinical validation trials, pilot deployment following regulatory authorisation, Advisory Board participation, and providing EHR integration input. Early partners receive preferential access, pricing, and product development input. Request information for NHS trusts

For all enquiries, contact Maximus Smith, Founder at maximus.smith@heaith.co.uk with a clear subject line (Clinical Advisory Board, Investment Inquiry, NHS Partnership, Demo Request, Regulatory Status, or General Inquiry). We aim to respond within 48 hours.